Abbott EVP awarded stock option and RS grant

Moreland Mary K reported acquisition or exercise transactions in this Form 4 filing.

Rhea-AI Filing Summary

Moreland Mary K reported acquisition or exercise transactions in this Form 4 filing.

Abbott Laboratories executive vice president Mary K. Moreland reported equity awards on common stock. She received an employee stock option covering 57,512 shares that vests in three annual installments starting February 24, 2027, and a performance-based restricted stock award of 13,951 shares with a three-year term tied to return-on-equity targets.

Insider Trade Summary

Grant/Award: 71,463 shares

Grant/Award 3 txns

Insider Moreland Mary K

Role EXECUTIVE VICE PRESIDENT

Type	Security	Shares	Price	Value
Grant/Award	Option (right to buy)	57,512	$0.00	$0.00
Grant/Award	Common shares without par value	13,951	$0.00	$0.00
holding	Common shares without par value	--	--	--

Holdings After Transaction: Option (right to buy) — 57,512 contracts (Direct); Common shares without par value — 109,534 shares (Direct); Common shares without par value — 11,845 shares (Indirect, Profit Sharing Trust)

Footnotes (3)

1. F1. These shares represent a performance-based restricted stock award under the Abbott Laboratories 2017 Incentive Stock Program. The award has a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The award includes the right to have shares withheld for tax purposes.
2. F2. Balance in the Abbott Laboratories Stock Retirement Trust as of February 24, 2026.
3. F3. Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 19,170 on February 24, 2027, 19,171 on February 24, 2028, and 19,171 on February 24, 2029.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Abbott Laboratories (ABT) executive Mary K. Moreland report on this Form 4?

Mary K. Moreland reported equity awards in Abbott Laboratories stock. She received an option for 57,512 shares and a performance-based restricted stock award of 13,951 shares, both granted under the Abbott Laboratories 2017 Incentive Stock Program on February 24, 2026.

How many Abbott Laboratories options did Mary K. Moreland acquire?

Mary K. Moreland acquired an employee stock option covering 57,512 Abbott Laboratories shares. The option was granted under the 2017 Incentive Stock Program and becomes exercisable in three annual increments beginning on February 24, 2027, then February 24, 2028, and February 24, 2029.

What are the terms of Mary K. Morelands performance-based restricted stock award in ABT?

The performance-based restricted stock award covers 13,951 Abbott Laboratories shares. It has a three-year term, with no more than one-third vesting in any single year, and vesting requires Abbott to reach a minimum return-on-equity target, with shares eligible to be withheld for taxes.

Under which plan were Mary K. Morelands Abbott equity awards granted?

Both the stock option and the performance-based restricted stock award were granted under the Abbott Laboratories 2017 Incentive Stock Program. The option grant is described as exempt from Section 16 under Rule 16b-3, reflecting its status as a compensatory employee award.

How do the vesting increments work for Mary K. Morelands Abbott stock option?

The stock option becomes exercisable in three tranches: 19,170 shares on February 24, 2027, 19,171 shares on February 24, 2028, and 19,171 shares on February 24, 2029. These annual increments structure the exercisability of the full 57,512-share option grant over time.

What indirect Abbott Laboratories holdings were reported for Mary K. Moreland?

An indirect holding balance was reported in the Abbott Laboratories Stock Retirement Trust. The filing notes this balance as of February 24, 2026, and identifies it as a profit-sharing trust position, separate from her directly held common shares and newly granted equity awards.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/26/2026 - 06:43 PM EST Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Moreland Mary K

(Last) (First) (Middle)

100 ABBOTT PARK ROAD

(Street)

ABBOTT PARK IL 60064

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ABBOTT LABORATORIES [ ABT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EXECUTIVE VICE PRESIDENT

3. Date of Earliest Transaction (Month/Day/Year)
02/24/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common shares without par value	02/24/2026		A		13,951(1)	A	$0	109,534	D
Common shares without par value								11,845(2)	I	Profit Sharing Trust

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Option (right to buy)(3)	$114.6	02/24/2026		A		57,512		02/24/2027	02/23/2036	Common Shares	57,512	$0	57,512	D

Explanation of Responses:

1. These shares represent a performance-based restricted stock award under the Abbott Laboratories 2017 Incentive Stock Program. The award has a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The award includes the right to have shares withheld for tax purposes.

2. Balance in the Abbott Laboratories Stock Retirement Trust as of February 24, 2026.

3. Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 19,170 on February 24, 2027, 19,171 on February 24, 2028, and 19,171 on February 24, 2029.

	/s/ Mary K. Moreland by Jessica H. Paik, Attorney-in-Fact	02/26/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.